Fabio
3.0 KiB
3.0 KiB
type, title, description, jurisdiction, legislature, session, identifier, citation, classification, subjects, status, primary_sponsors, version_count, action_count, vote_count, first_action, last_action, source, source_identifier, source_url, source_hash, vintage, source_snapshot, retrieved_at, confidence, tags
| type | title | description | jurisdiction | legislature | session | identifier | citation | classification | subjects | status | primary_sponsors | version_count | action_count | vote_count | first_action | last_action | source | source_identifier | source_url | source_hash | vintage | source_snapshot | retrieved_at | confidence | tags | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bill | Relates to adverse determinations related to a step therapy protocol override determination; repealer | Requires written notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination which includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent. | us/states/ny | New York Legislature | 2023-2024 | A 8501 | New York A 8501 (2023-2024) |
|
enacted |
|
1 | 12 | 2 | 2024-01-04 | 2024-02-07 | openstates | ocd-bill/6f52e532-f632-4b4b-a786-82da86f298cd | http://www.nysenate.gov/legislation/bills/2023/A8501 | 1da9360ffe1983e39547c53b9a4fe2fa2e7f8e716f9006e95820457f87d47ba9 | 2026-07-01 | https://data.openstates.org/daily/2026-07-01/public.pgdump | 2026-07-06 | reported |
|
New York A 8501 (2023-2024) — Relates to adverse determinations related to a step therapy protocol override determination; repealer
Requires written notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination which includes the clinical review criteria relied upon to make such determination and any applicable alternative prescription drugs subject to the step therapy protocol of the utilization review agent.
Version chain
The bill's text revisions, in order — the diff chain from filing to enrollment.
- A8501 (committee substitute) — source
Votes
- Floor Vote — 59–0 (pass) · upper
- Assembly Vote — 139–2 (pass) · lower
Sponsors
- John T. McDonald III — primary (person)
Timeline
The legislative action history — every referral, reading, and vote.
- 2024-01-04 REFERRED TO INSURANCE
referral-committee - 2024-01-08 REPORTED
- 2024-01-11 ADVANCED TO THIRD READING CAL.214
- 2024-01-16 PASSED ASSEMBLY
passage - 2024-01-16 DELIVERED TO SENATE
- 2024-01-16 REFERRED TO RULES
referral-committee - 2024-01-29 SUBSTITUTED FOR S8038
- 2024-01-29 3RD READING CAL.38
- 2024-01-29 PASSED SENATE
passage - 2024-01-29 RETURNED TO ASSEMBLY
- 2024-02-07 DELIVERED TO GOVERNOR
executive-receipt - 2024-02-07 SIGNED CHAP.28
executive-signature
Source
OpenStates / OpenCivicData bulk snapshot 2026-07-01; origin ocd-bill/6f52e532-f632-4b4b-a786-82da86f298cd. Confidence: reported (aggregated from official New York legislature records).